Efficacy and safety of Olaparib treatment for advanced or recurrent breast cancer (OPTIMAL study)
Not Applicable
Recruiting
- Conditions
- HER2 negative advanced or recurrence (metastatic) breast cancer
- Registration Number
- JPRN-UMIN000050600
- Lead Sponsor
- Japan Breast Cancer Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 155
Inclusion Criteria
Not provided
Exclusion Criteria
Patients for whom written consent could not be obtained in the prospective observational study. Patients in the retrospective observational study who offered refusal by opt-out.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method